Patents Assigned to Xenon Pharmaceuticals Inc.
  • Patent number: 11325902
    Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: May 10, 2022
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Kristen Nicole Burford, Thilo Focken, Verner Alexander Lofstrand, Michael Scott Wilson, Alla Yurevna Zenova
  • Patent number: 11299490
    Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: April 12, 2022
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Jean-Christophe Andrez, Kristen Nicole Burford, Sultan Chowdhury, Charles Jay Cohen, Christoph Martin Dehnhardt, Robert Joseph Devita, James Roy Empfield, Thilo Focken, Michael Edward Grimwood, Syed Abid Hasan, James Philip Johnson, Jr., Alla Yurevna Zenova
  • Publication number: 20220062266
    Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 3, 2022
    Applicant: Xenon Pharmaceuticals Inc.
    Inventor: Gregory N. BEATCH
  • Publication number: 20220064120
    Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.
    Type: Application
    Filed: July 6, 2021
    Publication date: March 3, 2022
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Paul Robert BICHLER, Jean-Jacques Alexandre CADIEUX, Matthew David TANDY, Gregory N. BEATCH
  • Publication number: 20220055977
    Abstract: The invention provides a method of treating a disease or condition in a mammal by administering a compound having the general formula I: or a pharmaceutically acceptable salt thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 24, 2022
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Ivan William HEMEON, Brian SAFINA, Daniel SUTHERLIN
  • Patent number: 11203572
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: December 21, 2021
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS, INC
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Steven McKerrall, Daniel Sutherlin
  • Patent number: 11174268
    Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: November 16, 2021
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Jean-Christophe Andrez, David Earl Bogucki, Kristen Nicole Burford, Sultan Chowdhury, Charles Jay Cohen, Shannon Marie Decker, Christoph Martin Dehnhardt, Robert Joseph Devita, James Roy Empfield, Thilo Focken, Michael Edward Grimwood, Syed Abid Hasan, Qi Jia, James Philip Johnson, Jr., Michael Scott Wilson, Alla Yurevna Zenova
  • Patent number: 11149002
    Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: October 19, 2021
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Philippe Bergeron, Paul Robert Bichler, Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Wei Gong, Michael Edward Grimwood, Abid Hasan, Ivan William Hemeon, Qi Jia, Brian Salvatore Safina, Shaoyi Sun, Michael Scott Wilson, Alla Yurevna Zenova
  • Patent number: 11135214
    Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: October 5, 2021
    Assignee: Xenon Pharmaceuticals Inc.
    Inventor: Gregory N. Beatch
  • Patent number: 11130726
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 28, 2021
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Ivan William Hemeon, Brian Salvatore Safina, Daniel Sutherlin
  • Publication number: 20210253548
    Abstract: The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, n, ring A, X2, L, m, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: January 19, 2021
    Publication date: August 19, 2021
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Chien-an CHEN, Sultan CHOWDHURY, Shannon Marie DECKER, Christoph Martin DEHNHARDT, Ivan William HEMEON, Steven MCKERRALL, Brian SAFINA, Tao SHENG, Dan SUTHERLIN
  • Patent number: 11091441
    Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: August 17, 2021
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Paul Robert Bichler, Jean-Jacques Alexandre Cadieux, Matthew David Tandy, Gregory N. Beatch
  • Publication number: 20210213009
    Abstract: In certain embodiments, the present disclosure is directed to methods for treating pain in a subject, such as a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the subject in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.
    Type: Application
    Filed: December 14, 2020
    Publication date: July 15, 2021
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: James Philip JOHNSON, JR., Gregory N. BEATCH
  • Publication number: 20210171516
    Abstract: The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: September 24, 2020
    Publication date: June 10, 2021
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Philippe BERGERON, Kristen BURFORD, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Abid HASAN, Kwong Wah LAI, Zhiguo LIU, Steven MCKERRALL, Teresa Phuongtram NGUYEN, Brian Salvatore SAFINA, Daniel SUTHERLIN, Tao WANG
  • Publication number: 20210161886
    Abstract: In certain embodiments, the present disclosure is directed to methods for treating depressive disorders in a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.
    Type: Application
    Filed: November 9, 2020
    Publication date: June 3, 2021
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Cynthia Louise HARDEN, Gregory N. BEATCH
  • Publication number: 20210155588
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: September 3, 2020
    Publication date: May 27, 2021
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Steven MCKERRALL, Daniel SUTHERLIN
  • Publication number: 20210147363
    Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.
    Type: Application
    Filed: October 13, 2020
    Publication date: May 20, 2021
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Paul Robert BICHLER, Jean-Jacques Alexandre CADIEUX, Matthew David TANDY, Gregory N. BEATCH
  • Patent number: 10981905
    Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: April 20, 2021
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Jean-Christophe Andrez, Kristen Nicole Burford, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Qi Jia, Verner Alexander Lofstrand, Shaoyi Sun, Steven Sigmund Wesolowski, Michael Scott Wilson, Alla Yurevna Zenova
  • Publication number: 20210093618
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: November 7, 2019
    Publication date: April 1, 2021
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe ANDREZ, Paul Robert BICHLER, Chien-An CHEN, Sultan CHOWDHURY, Shannon Marie DECKER, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Qi JIA, Jun LI, Zhiguo LIU, Daniel F. ORTWINE, Brian Salvatore SAFINA, Daniel SUTHERLIN, Tao SHENG, Shaoyi SUN, Andrew D. WHITE, Michael Scott WILSON, Alla Yurevna ZENOVA, Jiuxiang ZHU
  • Publication number: 20210078947
    Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: December 3, 2019
    Publication date: March 18, 2021
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe ANDREZ, Philippe BERGERON, Paul Robert BICHLER, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Wei GONG, Michael Edward GRIMWOOD, Abid HASAN, Ivan William HEMEON, Qi JIA, Brian Salvatore SAFINA, Shaoyi SUN, Michael Scott WILSON, Alla Yurevna ZENOVA